1. Transcription factor Oct4 promotes osteosarcoma by regulating lncRNA AK055347
- Author
-
Hongwu Fan, Xiaoyu Yang, Changfu Zhao, Xue-Feng Li, and Guangyao Liu
- Subjects
musculoskeletal diseases ,0301 basic medicine ,Cancer Research ,Small interfering RNA ,Cell ,Articles ,Cell cycle ,Biology ,medicine.disease ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,medicine.anatomical_structure ,Oncology ,Downregulation and upregulation ,030220 oncology & carcinogenesis ,embryonic structures ,medicine ,Cancer research ,E2F1 ,Osteosarcoma ,Induced pluripotent stem cell ,neoplasms ,Transcription factor - Abstract
Osteosarcoma is the most common primary bone tumor in children and adolescents, typically presenting with a poor prognosis. Octamer-binding transcription factor 4 (Oct4) protein, encoded by the POU class 5 homeobox 1 gene, is important in maintaining self-renewal of pluripotent stem cells, and is closely associated with cancer. However, its role in osteosarcoma remains to be elucidated. The present study observed Oct4 was markedly increased in osteosarcoma cell lines and in human osteosarcoma tissue samples. Following Oct4 downregulation by small interfering RNA (siRNA) in osteosarcoma F5M2 cells, the cells exhibited significant decreases in proliferation and invasion ability, and an increase in cell apoptosis. Notably, downregulation of Oct4 decreased the expression of AK055347, a newly identified long noncoding RNA (lncRNA) in human tissues. The downregulation of AK055347 by siRNA resulted in a significant suppressive effect on proliferative and invasive ability, and promotion of cell apoptosis in osteosarcoma cells. Thus, the current study suggests Oct4 exerts a promoting effect in osteosarcoma, and identifies a novel lncRNA in osteosarcoma progression.
- Published
- 2016